David Sallman
Moffitt Cancer Center · Moffitt Cancer Center, Tampa, US · H. Lee Moffitt Cancer Center and Research Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Sallman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:17 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06660368 · BCL2i CLAG-M in R/R Acute Myeloid LeukemiaH. Lee Moffitt Cancer Center and Research Institute · recruiting · Relapsed or Refractory Acute Myeloid Leukemia (AML) · principal investigator
- Ph3NCT03745716 · APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)Aprea Therapeutics · completed · MDS · principal investigator
- Ph1/Ph2NCT03072043 · Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid NeoplasmsH. Lee Moffitt Cancer Center and Research Institute · completed · Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Neoplasm · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:17 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- 437 citationsRCR 23.2
- Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).J Clin Oncol · 2021263 citationsRCR 13.3
- Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.J Clin Oncol · 2023182 citationsRCR 15.3
- 135 citationsRCR 10.8
- 104 citationsRCR 8.0
- Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.Lancet Haematol · 202381 citationsRCR 6.9
- Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.EBioMedicine · 201875 citationsRCR 2.5
- 71 citationsRCR 16.3
- Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.Blood Adv · 202449 citationsRCR 5.9
- Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia.Blood · 202046 citationsRCR 1.8